Update on guidelines for management of hypercholesterolemia

@article{Mannu2012UpdateOG,
  title={Update on guidelines for management of hypercholesterolemia},
  author={Gurdeep S. Mannu and M. Justin S. Zaman and Abhaya R. Gupta and Habib U. Rehman and Phyo Kyaw Myint},
  journal={Expert Review of Cardiovascular Therapy},
  year={2012},
  volume={10},
  pages={1239 - 1249}
}
Coronary heart disease (CHD) is a leading cause of morbidity and mortality globally. Hypercholesterolemia is one of the major risk factors for CHD. With the increase in aging populations and progressively sedentary lifestyles, the global burden of CHD is likely to increase in the future despite better preventive strategies. It is vitally important to manage hypercholesterolemia effectively because it is a modifiable risk factor. At present, there are several guidelines with differences in… 

Patients with Small Abdominal Aortic Aneurysm are at Significant Risk of Cardiovascular Events and this Risk is not Addressed Sufficiently.

Multi-Centre Study on Cardiovascular Risk Management on Patients Undergoing AAA Surveillance.

  • A. SaratzisN. Dattani P. Stather
  • Medicine
    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery
  • 2017

Rheumatic Mitral Valve Disease Is Associated With Worse Outcomes in Stroke: A Thailand National Database Study

RMVD is associated with the development of cardiac arrest, shock, arrhythmias, respiratory failure, pneumonia, and sepsis after acute stroke.

SCREENING OF THE POTENTIAL ANTIHYPERCHOLESTERMIC ACTIVITY OF SOME EGYPTIAN HERBS

Garden nasturtium and onion extracts have dual effect in reducing blood cholesterol and keep the normal appearance of blood vessel.

Intervention Associated Acute Kidney Injury and Long-Term Cardiovascular Outcomes

Investigation in patients undergoing open (OAR) or endovascular (EVAR) abdominal aortic aneurysm repair found AKI is associated with long-term CV events after surgery orendovascular intervention, and this was confirmed in other CV-interventions.

Raphanus sativus ameliorates atherogeneic lipid profiles in hypercholesterolemic rats and hypercholesterolemia-associated peroxidative liver damage

R. sativus extract lowers the cardiovascular disease risk factors under hypercholesterolemic situation by increasing the plasma/hepatic clearance of cholesterol and improving the hypercholesterololemia-induced oxidative damage of hepatic tissues.

The Protective Effect of White and Red Radish as Hypoglycemic and Hypocholesterolemic Agents

Radish, Raphanus Sativus L. (family: Brassicaceae) has been recognized since ancient times, roots and leaves are used for cooking and treatment of a wide variety ailments. White radish leaves (WRL),

IONTOPHORESIS OF FLUVASTATIN SODIUM: STUDY OF VARIOUS FACTOR AND IN- VITRO PERMEATION

Fluvastatin sodium (FVS) is the first fully synthetic 3hydroxy-3-methylglutaryl coenzyme (HMG-CoA) reductase inhibitors used for the treatment of hypercholesterolemia. It shows extensive first pass

References

SHOWING 1-10 OF 82 REFERENCES

British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary

This guideline reinforces the view that doctors should not focus solely on blood pressure but must also formally assess total risk of cardiovascular disease and use multifactorial interventions, including statins and aspirin, to reduce it.

Secondary prevention of coronary heart disease: the role of fibric acids.

Themisclassification of key variables reduces the significance of relations in longitudinal studies, and it may also affect clinical trials by allowing the inclusion of subjects with, for example, elevated triglyceride levels but a low risk of CHD, and the direct measurement of apoB may improve the selection of patients in clinical trials.

Progressing from risk factors to omics.

  • P. Wilson
  • Medicine
    Circulation. Cardiovascular genetics
  • 2008
Progress has been made from traditional risk factor assessment to the present time that includes newer assessment methods such as genomics, metabolomics, and predictive medicine, emphasizing the progress made in research and care for clinical atherosclerotic disease.

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

Pravastatin did not reduce either all-cause mortality or CHD significantly when compared with usual care in older participants with well-controlled hypertension and moderately elevated LDL-C.

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia

Treatment with pravastatin significantly reduced the incidence of myocardial infarction and death from cardiovascular causes without adversely affecting the risk of death from noncardiovascular causes in men with moderate hypercholesterolemia and no history of my Cardiac Infarction.

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

These Joint ESC/European Atherosclerosis Society (EAS) guidelines on the management of dyslipidaemias are complementary to the guidelines on CVD prevention in clinical practice and address not only physicians but also specialists from lipid clinics or metabolic units who are dealing with dyslipIDAemias that are more difficult to classify and treat.

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Treatment with pravastatin significantly reduced the incidence of myocardial infarction and death from cardiovascular causes without adversely affecting the risk of death from noncardiovascular causes in men with moderate hypercholesterolemia and no history of my Cardiac Infarction.

[Detection, evaluation, and treatment of high blood cholesterol in adults].

This report advocates more intensive treatment in order to reduce low-density lipoprotein (LDL) cholesterol in specific groups of individuals and recognizes as a secondary prevention concern a cluster of heart disease risk factors known as "the metabolic syndrome".
...